Mastek Q4FY26 Revenue at ₹938 Crore, Up 3.6% YoY; Proposes ₹16 Dividend
Mastek reported Q4FY26 revenue of ₹938.0 crore, up 3.6% YoY, with a 12-month order backlog growing 24.4% YoY to ₹2,849.2 crore. The company closed over 25 AI deals in the quarter. A final dividend of ₹16 per share (480% for FY26) was proposed. New CFO and CHRO were appointed.
The announcement includes key financial metrics like revenue growth, order backlog, dividend declaration, and strategic wins, which are material information for investors and stakeholders. The positive financial performance and strategic advancements significantly impact the company's valuation and investor confidence.
The company reported revenue growth, increased order backlog, significant AI deal closures, and proposed a higher dividend, indicating positive financial performance and future outlook. The appointment of new key personnel also suggests a focus on strengthening leadership.
Mastek Limited announced its financial results for the fourth quarter and full year of FY26, ending March 31, 2026. The company reported Q4FY26 revenue of ₹938.0 crore, marking a 3.6% year-on-year increase. This growth was supported by a 24.4% year-on-year increase in the 12-month order backlog, reaching ₹2,849.2 crore.
Umang Nahata, Chief Executive Officer of Mastek, highlighted the company's strong momentum driven by over 25 AI-assisted deals closed in the quarter, contributing to a full-year total of 85+ deals. The UK business continued to lead growth at 21.8% in INR terms for FY26, with a significant 95% year-on-year growth in the healthcare sector. The company also strengthened its leadership team with the appointment of a new Chief Financial Officer and Chief Human Resources Officer.
Deepak Kedia, Chief Financial Officer, noted resilient performance with operating EBITDA margins at 16.1% and PAT margins at 11.0%. The company achieved a healthy addition to cash and cash equivalents of ₹139.7 crore, resulting in a closing balance of ₹938.5 crore. Reflecting its commitment to shareholder returns, the Board recommended a final dividend of ₹16 per share, aggregating to 480% for the year, an increase from 460% in FY25.
Key wins for the quarter included securing a strategic engagement to implement a unified, federal-level patient data system for a US Federal health authority, establishing the UK's first AI Centre of Excellence for a global financial services provider, and delivering a unified Financial Management platform for a leading South-East Asian government-backed insurer. The company also received several industry recognitions from ISG, Avasant, Gartner, and IDC for its capabilities in AI, healthcare, and cloud services.
What to do with a filing like this
Mastek Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mastek Limited. Read the original for the full detail.